CANNIBICS PHARMACEUT (CNBX)

1.01 +0.05 ( +5.21% ) 16

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

Instant Analysis On Any Stock…

Your Marijuana Trend Report Is Ready!

 

CNBX Detailed Quote

Last Trade:   1.01
Trade Time:   1:07pm
Change:   +0.05
Perc Change:   +5.21%
Prev Close:   0.96
Open:   0.95
Day's Range:   0.95 - 1.03
Bid:   N/A
EPS   -0.01
52wk Range:   0.04 - 7.60
Volume:   76512
Avg Vol:   495231
Market Cap:   119.51M
P/E (ttm):   N/A
PES (ttm):   -0.01
Ask:   N/A

CNBX Recent Headlines

  • Cannabics Pharmaceuticals Establishes a Human-Cannabis-Cancer Genetics lab to Expand its Personalized Diagnostics 07/24/2017 12:45 PMCannabics Pharmaceuticals Inc. (OTC-QB: CNBX) today announced it has established a Genetic lab that will develop diagnostic tools based on human genome, tumor genetics and cannabinoids. The company recruited Dr. Moran Grinberg to serve as its VP of R&D and to lead the Genetic research. Moran has a PhD in Virology and MSc in clinical pharmacology with vast experience in conceptualizing and executing pharmacological research.
  • Cannabics Pharmaceuticals Executed a Final Collaboration Agreement with SIMFO GmbH 07/12/2017 12:45 PMCannabics Pharmaceuticals Inc. (CNBX) today announced it has executed a Collaboration Agreement with SIMFO GmbH, a world leader in cancer diagnostics and liquid biopsies located in Germany. Under the Agreement, Cannabics Pharmaceuticals shall be the exclusive global provider of SIMFO's CTC diagnostics to cancer patients treated with natural cannabinoids. The diagnostics include a count of circulating tumor cells (CTC) and drug sensitivity tests of different cannabinoids (e.g.
  • Cannabics Pharmaceuticals Receives Positive Results in Drug Sensitivity Tests on CTCs 06/30/2017 12:30 PMCannabics Pharmaceuticals Inc. (CNBX) today announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids CBD and CBDA. In addition, the screening results which indicate varied effectiveness of the tested cannabinoids upon different tumors (colon, breast, prostate) reaffirm the use of our proprietary technology in providing supportive data for personalized treatments. Dr. Eyal Ballan, CTO of Cannabics Pharmaceuticals noted "The screening of CTCs treated with specific cannabinoids and CTC cell count of patients treated with cannabinoids produces an invaluable body of data in our search for effective anti-tumor treatment".
  • Cannabics Pharmaceuticals Inc. Provides Shareholders Update June 2017 06/02/2017 01:39 PMCannabis has the potential of being a natural cancer attenuator comprising numerous active compounds which interact with human cells in a complex manner. Understanding the biological mechanism is a long and profound process, yet, utilizing diagnostic lab tests and clinical studies this potential can be unraveled. Cannabics Pharmaceuticals engages in various technologies and studies that together create the knowledge of treating cancer patients with cannabis.
  • Cannabics Pharmaceuticals Raises $3,000,000 in Capital Raise Transaction 05/10/2017 01:10 PMCannabics Pharmaceuticals Inc. (CNBX) today announced it has entered into a securities purchase agreement with D-Beta One EQ, Ltd. ("D-Beta"). D-Beta will purchase 3,000,000 shares of common stock (the "Purchased Shares") at a purchase price of $1.00 per share, for aggregate proceeds of $3.0 million and may purchase up to an additional 1,500,000 shares of common stock (the "Additional Shares") at a purchase price of $2.00 per share over the next 12 months. Pursuant to the Purchase Agreement, Cannabics Pharmaceuticals is required to register all shares previously acquired by D-Beta or its affiliates, the Purchased Shares, and the Additional Shares.

FIND OUT HOW MUCH MOMENTUM IS DRIVING YOUR MARIJUANA STOCK!

AS SEEN ON
>>